Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study.
biomarkers
cardiovascular diseases
heart failure
protein interaction maps
proteomics
Journal
Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
medline:
18
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
ppublish
Résumé
We sought to identify protein biomarkers of new-onset heart failure (HF) in 3 independent cohorts (HOMAGE cohort [Heart Omics and Ageing], ARIC study [Atherosclerosis Risk in Communities], and FHS [Framingham Heart Study]) and assess if and to what extent they improve HF risk prediction compared to clinical risk factors alone. A nested case-control design was used with cases (incident HF) and controls (without HF) matched on age and sex within each cohort. Plasma concentrations of 276 proteins were measured at baseline in ARIC (250 cases/250 controls), FHS (191/191), and HOMAGE cohort (562/871). In single protein analysis, after adjusting for matching variables and clinical risk factors (and correcting for multiple testing), 62 proteins were associated with incident HF in ARIC, 16 in FHS, and 116 in HOMAGE cohort. Proteins associated with incident HF in all cohorts were BNP (brain natriuretic peptide), NT-proBNP (N-terminal pro-B-type natriuretic peptide), eukaryotic translation initiation factor 4E-BP1 (4E-binding protein 1), hepatocyte growth factor (HGF), Gal-9 (galectin-9), TGF-alpha (transforming growth factor alpha), THBS2 (thrombospondin-2), and U-PAR (urokinase plasminogen activator surface receptor). The increment in A multiprotein biomarker approach improves prediction of incident HF when added to natriuretic peptides and clinical risk factors.
Sections du résumé
BACKGROUND
We sought to identify protein biomarkers of new-onset heart failure (HF) in 3 independent cohorts (HOMAGE cohort [Heart Omics and Ageing], ARIC study [Atherosclerosis Risk in Communities], and FHS [Framingham Heart Study]) and assess if and to what extent they improve HF risk prediction compared to clinical risk factors alone.
METHODS
A nested case-control design was used with cases (incident HF) and controls (without HF) matched on age and sex within each cohort. Plasma concentrations of 276 proteins were measured at baseline in ARIC (250 cases/250 controls), FHS (191/191), and HOMAGE cohort (562/871).
RESULTS
In single protein analysis, after adjusting for matching variables and clinical risk factors (and correcting for multiple testing), 62 proteins were associated with incident HF in ARIC, 16 in FHS, and 116 in HOMAGE cohort. Proteins associated with incident HF in all cohorts were BNP (brain natriuretic peptide), NT-proBNP (N-terminal pro-B-type natriuretic peptide), eukaryotic translation initiation factor 4E-BP1 (4E-binding protein 1), hepatocyte growth factor (HGF), Gal-9 (galectin-9), TGF-alpha (transforming growth factor alpha), THBS2 (thrombospondin-2), and U-PAR (urokinase plasminogen activator surface receptor). The increment in
CONCLUSIONS
A multiprotein biomarker approach improves prediction of incident HF when added to natriuretic peptides and clinical risk factors.
Identifiants
pubmed: 37192292
doi: 10.1161/CIRCHEARTFAILURE.122.009694
pmc: PMC10179982
doi:
Substances chimiques
Biomarkers
0
Natriuretic Peptide, Brain
114471-18-0
Peptide Fragments
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e009694Références
Am J Epidemiol. 1989 Apr;129(4):687-702
pubmed: 2646917
J Am Heart Assoc. 2018 Jul 13;7(14):
pubmed: 30006491
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Lancet. 2001 Aug 11;358(9280):432-4
pubmed: 11513900
Am Heart J. 2003 Oct;146(4):581-90
pubmed: 14564310
J Gerontol A Biol Sci Med Sci. 2013 May;68(5):617-23
pubmed: 23109678
Eur J Heart Fail. 2018 Jan;20(1):55-62
pubmed: 28967680
J Am Heart Assoc. 2017 May 2;6(5):
pubmed: 28465299
Eur J Heart Fail. 2012 Jul;14(7):718-29
pubmed: 22562498
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Circulation. 2017 Apr 25;135(17):1651-1664
pubmed: 28438806
Am J Cardiol. 1999 Nov 15;84(10):1192-7
pubmed: 10569329
J Biomed Res. 2014 Sep;28(5):349-59
pubmed: 25332706
Eur J Heart Fail. 2011 May;13(5):528-36
pubmed: 21454299
J Am Coll Cardiol. 2017 Aug 8;70(6):776-803
pubmed: 28461007
Nucleic Acids Res. 2011 Aug;39(15):e102
pubmed: 21646338
BMC Bioinformatics. 2011 Nov 09;12:436
pubmed: 22070249
Heart. 2000 May;83(5):596-602
pubmed: 10768918
Eur J Heart Fail. 2014 Apr;16(4):377-83
pubmed: 24464777
Phys Rev E Stat Nonlin Soft Matter Phys. 2004 Feb;69(2 Pt 2):026113
pubmed: 14995526
Circ Heart Fail. 2015 May;8(3):438-47
pubmed: 25737496
Stat Appl Genet Mol Biol. 2007;6:Article27
pubmed: 18052910
Bioinformatics. 2010 Dec 15;26(24):3135-7
pubmed: 21123224
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Circulation. 2012 Sep 25;126(13):1596-604
pubmed: 22907935
Circ Heart Fail. 2019 May;12(5):e005897
pubmed: 31104495
Int J Cardiol. 2017 Dec 1;248:361-368
pubmed: 28728851
Int J Cardiol. 2020 Feb 1;300:252-254
pubmed: 31761405
BMJ. 2016 Feb 25;352:i969
pubmed: 26916049
J Am Coll Cardiol. 2013 Jul 23;62(4):263-71
pubmed: 23684677
Lancet. 2018 Feb 10;391(10120):572-580
pubmed: 29174292